Sumitomo Pharma Oncology, Inc. Pursues Research and Discovery with Persistence – Featured in Pharma Tech Outlook

June 30, 2022

Sumitomo Pharma Oncology, Inc. (SMP Oncology) and Steve Warner, Ph.D., Senior Vice President and Head of US Research at SMP Oncology, were recently featured in a Pharma Tech Outlook. In “Sumitomo Pharma Oncology: Discovering Immunotherapy Agents with Persistence,” Dr. Warner discusses SMP Oncology’s ongoing work in immunotherapy drug discovery, highlighting the progress with the Company’s investigational oral pyruvate kinase M2 (PKM2) activator, TP-1454.   

“TP-1454 further illustrates how we look at immunotherapy. Understanding how to best position this compound in the clinic required us to broaden our view of the immune system and how it functions in the context of the tumor microenvironment. Once we were able to connect the activation of PKM2 to tumor metabolism and immune function, we began to view TP-1454 as an immunomodulatory compound,” explains Dr. Warner.

Beyond examining the possible use of TP-1454 as a viable approach to targeting nutrient metabolism in tumors, SMP Oncology seeks to understand cancer treatment from a holistic perspective, inclusive of all of the complexities of tumor biology, to create innovative therapies.